Icosapent ethyl therapy for very high triglyceride levels: a 12-week, multi-center, placebo-controlled, randomized, double-blinded, phase III clinical trial in China

OBJECTIVES: Eicosapentaenoic acid in its ethyl ester form is the single active component of icosapent ethyl (IPE). This study was a phase III, multi-center trial assessing the safety and efficiency of IPE for treating very high triglyceride (TG) in a Chinese cohort. METHODS: Patients having TG level...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhen, Zhang, Xin, Qu, Yanling, Zhang, Shuyang, Chen, Yundai, Chen, Xiaoping, Qi, Xin, Liu, Peijing, Liu, Shuqin, Jiang, Shan, Man, Ronghai, He, Liping, Wu, Ling, Li, Zhanquan, Shang, Yijun, Qiu, Zhaohui, Liu, Feng, Xu, Chenhong, Lai, Chunlin, Ge, Junbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10257163/
https://www.ncbi.nlm.nih.gov/pubmed/37301827
http://dx.doi.org/10.1186/s12944-023-01838-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10257163/
https://www.ncbi.nlm.nih.gov/pubmed/37301827
http://dx.doi.org/10.1186/s12944-023-01838-8

Ejemplares similares